(Health Korea News / Lee Si-woo) On the 6th, Yungjin Pharmaceutical (CEO Lee Ki-soo) announced that it signed a joint research and development agreement with Basgen Bio (CEO Kim Ho and Jang Il-tae) for the discovery of new targets for innovative anticancer drugs.
This is the second collaboration with Basgen Bio, following the signing of a joint research and development agreement for the expansion of imidazole derivative indications including KL1333 and the development of complex new drugs for chronic diseases in March.
Through this contract, Basgen Bio will discover five new targets related to colon cancer, go through the verification stage through experiments, and transfer the technology to Yungjin Pharmaceutical after discovering effective substances. Yungjin Pharmaceutical plans to solidify its position as an innovative new drug development company by receiving the target and effective substance technology.
For reference, Youngjin Pharmaceutical has not yet developed a single new drug approved by the Ministry of Food and Drug Safety, so its desire to have its own new drug is bound to be even greater.
CEO Lee Ki-soo said on this day, “We will strive to expand the new drug pipeline through open innovation R&D research and to leap forward as a global company that takes the lead in solving unmet medical needs through the development of innovative new drugs.”
Meanwhile, Yungjin Pharm introduced Basgen Bio as “a company that holds exclusive rights to use the blood-based biobank (K-Biobank) data of 156,000 people, and is discovering ideal novel targets (INTa) for innovative new drugs (First-in-class, FIC) based on a clinical multi-omics cohort of 770,000 people including multi-ethnic data.”
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
